Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor

Hoang M. Thai, Jason Wollmuth, Steven Goldman, Mohamed Gaballa

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

To determine whether angiotensin receptor blockade decreases vascular tone in heart failure by improving endothelial-dependent vasorelaxation and increasing nitric oxide (NO) bio-availability, we treated infarcted adult male Sprague-Dawley rats with candesartan for 7 days or 8 weeks (10 mg/kg/day in drinking water). Candesartan, at both time points, lowered left ventricular (LV) systolic pressure (P < 0.05) (122 ± 22 versus 74 ± 16 and 73 ± 10 mm Hg) and LV dP/dt (5914 ± 1294 versus 2857 ± 1672 versus 3175 ± 769 mm Hg/s), but lowered LV end-diastolic pressure only at 8 weeks (16.9 ± 9.7 versus 11.2 ± 5.7 versus 6.9 ± 5.3 mm Hg). The vasorelaxation response to acetylcholine (ACh) in thoracic aortic segments was decreased with infarction (P < 0.05), remained unchanged with 1 week of candesartan, but increased 84 and 86% at 10-4 and 10 -5 M ACh (P < 0.05) at 8 weeks. The enhanced candesartan-induced vasorelaxation at 8 weeks was abolished with NG-nitro-L-arginine methyl ester (200 μM). In bovine pulmonary endothelial cells, 20 μM candesartan increased endothelial nitric-oxide synthase (eNOS) protein levels (P < 0.05) (28.9 ± 2.6 versus 16.1 ± 3.7 intensity units/μg of protein); the increased eNOS was abolished by a specific angiotensin subtype 2 (AT2) receptor antagonist, PD 123319. These data suggest that AT1 receptor blockade enhances vasorelaxation in heart failure by increasing NO bioavailability, in part via an AT2 receptor-mediated up-regulation of eNOS protein.

Original languageEnglish (US)
Pages (from-to)1171-1178
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume307
Issue number3
DOIs
StatePublished - Dec 2003

Fingerprint

Nitric Oxide Synthase Type III
Angiotensins
Vasodilation
Up-Regulation
Heart Failure
Acetylcholine
Angiotensin II Type 2 Receptor Blockers
Nitric Oxide
Blood Pressure
Proteins
Angiotensin Receptors
NG-Nitroarginine Methyl Ester
Ventricular Pressure
Drinking Water
Infarction
Biological Availability
Blood Vessels
Sprague Dawley Rats
Thorax
Endothelial Cells

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{691cd37c4b9548b0a70d60f976371d7b,
title = "Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor",
abstract = "To determine whether angiotensin receptor blockade decreases vascular tone in heart failure by improving endothelial-dependent vasorelaxation and increasing nitric oxide (NO) bio-availability, we treated infarcted adult male Sprague-Dawley rats with candesartan for 7 days or 8 weeks (10 mg/kg/day in drinking water). Candesartan, at both time points, lowered left ventricular (LV) systolic pressure (P < 0.05) (122 ± 22 versus 74 ± 16 and 73 ± 10 mm Hg) and LV dP/dt (5914 ± 1294 versus 2857 ± 1672 versus 3175 ± 769 mm Hg/s), but lowered LV end-diastolic pressure only at 8 weeks (16.9 ± 9.7 versus 11.2 ± 5.7 versus 6.9 ± 5.3 mm Hg). The vasorelaxation response to acetylcholine (ACh) in thoracic aortic segments was decreased with infarction (P < 0.05), remained unchanged with 1 week of candesartan, but increased 84 and 86{\%} at 10-4 and 10 -5 M ACh (P < 0.05) at 8 weeks. The enhanced candesartan-induced vasorelaxation at 8 weeks was abolished with NG-nitro-L-arginine methyl ester (200 μM). In bovine pulmonary endothelial cells, 20 μM candesartan increased endothelial nitric-oxide synthase (eNOS) protein levels (P < 0.05) (28.9 ± 2.6 versus 16.1 ± 3.7 intensity units/μg of protein); the increased eNOS was abolished by a specific angiotensin subtype 2 (AT2) receptor antagonist, PD 123319. These data suggest that AT1 receptor blockade enhances vasorelaxation in heart failure by increasing NO bioavailability, in part via an AT2 receptor-mediated up-regulation of eNOS protein.",
author = "Thai, {Hoang M.} and Jason Wollmuth and Steven Goldman and Mohamed Gaballa",
year = "2003",
month = "12",
doi = "10.1124/jpet.103.054916",
language = "English (US)",
volume = "307",
pages = "1171--1178",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Angiotensin Subtype 1 Receptor (AT1) Blockade Improves Vasorelaxation in Heart Failure by Up-Regulation of Endothelial Nitric-Oxide Synthase via Activation of the AT2 Receptor

AU - Thai, Hoang M.

AU - Wollmuth, Jason

AU - Goldman, Steven

AU - Gaballa, Mohamed

PY - 2003/12

Y1 - 2003/12

N2 - To determine whether angiotensin receptor blockade decreases vascular tone in heart failure by improving endothelial-dependent vasorelaxation and increasing nitric oxide (NO) bio-availability, we treated infarcted adult male Sprague-Dawley rats with candesartan for 7 days or 8 weeks (10 mg/kg/day in drinking water). Candesartan, at both time points, lowered left ventricular (LV) systolic pressure (P < 0.05) (122 ± 22 versus 74 ± 16 and 73 ± 10 mm Hg) and LV dP/dt (5914 ± 1294 versus 2857 ± 1672 versus 3175 ± 769 mm Hg/s), but lowered LV end-diastolic pressure only at 8 weeks (16.9 ± 9.7 versus 11.2 ± 5.7 versus 6.9 ± 5.3 mm Hg). The vasorelaxation response to acetylcholine (ACh) in thoracic aortic segments was decreased with infarction (P < 0.05), remained unchanged with 1 week of candesartan, but increased 84 and 86% at 10-4 and 10 -5 M ACh (P < 0.05) at 8 weeks. The enhanced candesartan-induced vasorelaxation at 8 weeks was abolished with NG-nitro-L-arginine methyl ester (200 μM). In bovine pulmonary endothelial cells, 20 μM candesartan increased endothelial nitric-oxide synthase (eNOS) protein levels (P < 0.05) (28.9 ± 2.6 versus 16.1 ± 3.7 intensity units/μg of protein); the increased eNOS was abolished by a specific angiotensin subtype 2 (AT2) receptor antagonist, PD 123319. These data suggest that AT1 receptor blockade enhances vasorelaxation in heart failure by increasing NO bioavailability, in part via an AT2 receptor-mediated up-regulation of eNOS protein.

AB - To determine whether angiotensin receptor blockade decreases vascular tone in heart failure by improving endothelial-dependent vasorelaxation and increasing nitric oxide (NO) bio-availability, we treated infarcted adult male Sprague-Dawley rats with candesartan for 7 days or 8 weeks (10 mg/kg/day in drinking water). Candesartan, at both time points, lowered left ventricular (LV) systolic pressure (P < 0.05) (122 ± 22 versus 74 ± 16 and 73 ± 10 mm Hg) and LV dP/dt (5914 ± 1294 versus 2857 ± 1672 versus 3175 ± 769 mm Hg/s), but lowered LV end-diastolic pressure only at 8 weeks (16.9 ± 9.7 versus 11.2 ± 5.7 versus 6.9 ± 5.3 mm Hg). The vasorelaxation response to acetylcholine (ACh) in thoracic aortic segments was decreased with infarction (P < 0.05), remained unchanged with 1 week of candesartan, but increased 84 and 86% at 10-4 and 10 -5 M ACh (P < 0.05) at 8 weeks. The enhanced candesartan-induced vasorelaxation at 8 weeks was abolished with NG-nitro-L-arginine methyl ester (200 μM). In bovine pulmonary endothelial cells, 20 μM candesartan increased endothelial nitric-oxide synthase (eNOS) protein levels (P < 0.05) (28.9 ± 2.6 versus 16.1 ± 3.7 intensity units/μg of protein); the increased eNOS was abolished by a specific angiotensin subtype 2 (AT2) receptor antagonist, PD 123319. These data suggest that AT1 receptor blockade enhances vasorelaxation in heart failure by increasing NO bioavailability, in part via an AT2 receptor-mediated up-regulation of eNOS protein.

UR - http://www.scopus.com/inward/record.url?scp=0345167173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345167173&partnerID=8YFLogxK

U2 - 10.1124/jpet.103.054916

DO - 10.1124/jpet.103.054916

M3 - Article

C2 - 14560036

AN - SCOPUS:0345167173

VL - 307

SP - 1171

EP - 1178

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -